Hung-Jie Jeng
Adult Health · San Gabriel, CANPI 1518367887
Payments from drug & device makers
Across 156 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$469
- Amarin Pharma, Inc.$181
- Phathom Pharmaceuticals, Inc.$150
- Boehringer Ingelheim$142
- Lilly USA, LLC$139
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,306100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,128 |
| Amgen(2 entities) | 44 | $469 |
| Amarin Pharma, Inc. | 10 | $181 |
| Phathom Pharmaceuticals, Inc. | 6 | $150 |
| Boehringer Ingelheim | 5 | $142 |
| Lilly USA, LLC | 5 | $139 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| AbbVie | 5 | $115 |
| Abbott | 6 | $111 |
| Novo Nordisk | 6 | $110 |
| Almatica Pharma LLC | 6 | $99 |
| Novartis | 5 | $96 |
| Johnson & Johnson | 2 | $62 |
| Dexcom, Inc. | 2 | $37 |
| Bayer | 2 | $33 |
| Gilead | 1 | $32 |
| Merck | 2 | $32 |
| GSK | 1 | $31 |
| Vivus LLC | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,306 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 362 | $167,287 |
| ProliaDenosumab | 102 | $160,012 |
| Diclofenac Sodium | 153 | $141,035 |
| CreonLipase/Protease/Amylase | 73 | $128,692 |
| FarxigaDapagliflozin Propanediol | 140 | $110,958 |
| JardianceEmpagliflozin | 119 | $94,699 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 30 | $74,535 |
| JanuviaSitagliptin Phosphate | 96 | $65,289 |
| Icosapent Ethyl | 218 | $63,796 |
| Diclofenac Epolamine | 64 | $52,903 |
| RestasisCyclosporine | 94 | $50,412 |
| LinzessLinaclotide | 68 | $46,293 |
| Cyclosporine | 119 | $44,007 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 12 | $43,146 |
| RybelsusSemaglutide | 37 | $43,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $469 | $234,547132 claims |
| AbbVieCreon, Restasis, Linzess | $115 | $225,397235 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $1,128 | $133,956183 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $142 | $101,190134 claims |
| MerckJanuvia, Janumet, Janumet Xr | $32 | $94,864126 claims |
| Novo NordiskRybelsus, Ozempic | $110 | $78,58667 claims |
| Johnson & JohnsonXarelto | $62 | $29,22633 claims |
| GileadVemlidy | $32 | $24,43719 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $150 | $9,56414 claims |
| NovartisEntresto | $96 | $8,61713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in San Gabriel
- Karolina FaysmanLos Angeles$1.1M
- Siok-Hian Tay-KelleyStanford$611K
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.